Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LAMA3 siRNA is a small interfering RNA (siRNA) molecule designed to specifically silence the expression of the LAMA3 gene, which encodes the laminin subunit alpha 3, a component of extracellular matrix proteins critical for basement membrane structure, cell adhesion, proliferation, and migration. LAMA3 siRNA mediates post-transcriptional gene silencing by targeting LAMA3 mRNA, leading to its degradation and reduced LAMA3 protein production. Experimental studies, particularly in cholangiocarcinoma (CCA) cell lines, demonstrate that LAMA3 siRNA efficiently downregulates LAMA3A mRNA, resulting in reduced cancer cell proliferation, inhibition of cell adhesion and migration, and reversion of epithelial-to-mesenchymal transition (EMT) phenotypes. These findings suggest that LAMA3 siRNA has potential therapeutic value as an investigational cancer therapy and as a tool for functional genomics research[1][2][3][6][9][11].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LAMA3 siRNA.